These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16462818)

  • 1. Influences of fat restriction and lipase inhibition on gastric emptying in obesity.
    Mathus-Vliegen EM; van Ierland-van Leeuwen ML; Bennink RJ
    Int J Obes (Lond); 2006 Aug; 30(8):1203-10. PubMed ID: 16462818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity.
    Mathus-Vliegen EM; Van Ierland-Van Leeuwen ML; Terpstra A
    Aliment Pharmacol Ther; 2004 Mar; 19(5):601-11. PubMed ID: 14987329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal.
    Demarchi B; Vos R; Deprez P; Janssens J; Tack J
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1261-8. PubMed ID: 15191507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP; Avenell A; Broom J; Whitehead J
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
    Ellrichmann M; Kapelle M; Ritter PR; Holst JJ; Herzig KH; Schmidt WE; Schmitz F; Meier JJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3995-8. PubMed ID: 18647814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal.
    Ellrichmann M; Ritter PR; Otte JM; Schrader H; Banasch M; Brunke G; Herzig KH; Seebeck J; Schmidt WE; Schmitz F
    Regul Pept; 2007 Mar; 139(1-3):136-40. PubMed ID: 17175037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor.
    Borovicka J; Schwizer W; Guttmann G; Hartmann D; Kosinski M; Wastiel C; Bischof-Delaloye A; Fried M
    Gut; 2000 Jun; 46(6):774-81. PubMed ID: 10807887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric emptying, CCK release, and satiety in weight-stable obese subjects.
    Mathus-Vliegen EM; Van Ierland-Van Leeuwen ML; Roolker W
    Dig Dis Sci; 2005 Jan; 50(1):7-14. PubMed ID: 15712629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipase inhibition: a novel concept in the treatment of obesity.
    Drent ML; van der Veen EA
    Int J Obes Relat Metab Disord; 1993 Apr; 17(4):241-4. PubMed ID: 8387973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of free fatty acids in regulating gastric emptying and gallbladder contraction.
    Degen L; Matzinger D; Drewe J; Nisslé S; Maecke H; Lengsfeld H; Hadvary P; Beglinger C
    Digestion; 2006; 74(3-4):131-9. PubMed ID: 17220631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
    Drent ML; Larsson I; William-Olsson T; Quaade F; Czubayko F; von Bergmann K; Strobel W; Sjöström L; van der Veen EA
    Int J Obes Relat Metab Disord; 1995 Apr; 19(4):221-6. PubMed ID: 7627244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal.
    Goedecke JH; Barsdorf M; Beglinger C; Levitt NS; Lambert EV
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1479-85. PubMed ID: 14634678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.
    Enç FY; Ones T; Akin HL; Dede F; Turoğlu HT; Ulfer G; Bekiroğlu N; Haklar G; Rehfeld JF; Holst JJ; Ulusoy NB; Imeryüz N
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G482-9. PubMed ID: 19109408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
    JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.